

Flovent® HFA® (fluticasone propionate) – First-time authorized brand alternative

- On May 24, 2022, Prasco launched an authorized brand alternative of GSK's <u>Flovent HFA</u> (fluticasone propionate) inhalation aerosol.
- Flovent HFA is approved for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older.
- Inhaled fluticasone propionate is also available as brand inhalation powder (<u>Flovent Diskus®</u>) and another brand inhalation powder (<u>ArmonAir® Digihaler™</u>). Both of these carry the same indication as Flovent HFA except ArmonAir Digihaler is only indicated in 12 years and older.
- In addition, inhaled fluticasone propionate is available in combination with salmeterol as a generic
 and brand inhalation powder (<u>Advair® Diskus</u>), generic and brand powder aerosol (<u>AirDuo®</u>
 <u>RespiClick®</u>), and brand powder aerosol (<u>AirDuo DigiHaler®</u>). These are indicated for the
 treatment of asthma: Advair Diskus in 4 years and older; AirDuo RespiClick and AirDuo DigiHaler
 in 12 years and older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.